INTRODUCTION
For over a century, radioactive materials have been used extensively to treat human diseases that exhibit unwanted hyperproliferation of underlying cells, the primary example being cancer. Almost immediately after the discovery of radioactivity in 1896, sealed tubes containing 226 Ra, purified by Maria Sklodowska Curie were implanted in patients to treat gynecological cancers. In conventional external-beam radiotherapy (EBRT), radiation beams emanate from a linear accelerator with the source located about 1 m from the tumor.
However in brachytherapy, radioactive or miniature x-ray emitting sources are implanted directly into the tumor or placed at a short distance from the tumor. Brachytherapy has several advantages over EBRT, e.g., the higher degree of dose localization in the target volume, better normal tissue sparing, and lower costs. However, brachytherapy is generally an invasive modality that requires special procedures for the proper handling of radioactive materials to mitigate risks and hazards to medical personnel, family members, the general public, and of course to the patient. The American Association of Physicists in Medicine (AAPM) and the Groupe Européen de Curiethérapie-European Society for Radiotherapy and Oncology (GEC-ESTRO) have developed guidelines for the dosimetry and calibration of brachytherapy sources in several protocols such as the AAPM Task Group 43 report (TG-43), 1, 2 quality control and quality assurance (QA) for brachytherapy procedures such as the Task Group 56 report (TG-56) 3 and ESTRO-issued Booklet 8, 4 and clinical standards for source calibrations. 5, 6 There are limited guidelines for the dosimetric requirements of innovative brachytherapy devices or for implementation of new clinical applications.
Through the process of reviewing advances in the field and identifying instances where brachytherapy innovations were not optimally implemented, common weaknesses and opportunities were identified for improved evaluation methods. Formed in 2008, the charge of TG-167 entailed the following items:
(1) To review the current practice in the U.S. marketplace, current U.S. Food and Drug Administration (FDA) requirements for new brachytherapy sources, and the difficulties encountered regarding the dosimetry of novel brachytherapy sources for permanent implantation using examples such as the historical introduction of the model 200 103 Pd TheraSeed® source (Theragenics, Corp., Buford, GA) and the model CS-1 Rev2 131 Cs Proxcelan® source (IsoRay Medical, Inc., Richland, WA). (2) To review critical physical, dosimetric, and radiobiological issues that arise when a novel source is introduced for permanent interstitial brachytherapy such as calibration traceability, accuracy of dosimetry parameters, and choice of prescribed dose for equivalent results. Also, the need to receive pertinent information about the source design from the manufacturer will be outlined so that a proper evaluation of a novel source can be accomplished. (3) To develop consensus guidelines on the methodology for these dosimetry issues that can minimize the potential risk to the human subjects and maximize the efficiency with which these novel sources can be widely adopted for the benefit of patients. The overall objective is to highlight the critical issues and missing information that may affect the clinical response so that investigators address them as a deliberate part of their study design.
Brachytherapy has been and continues to be an area of intense research interest. [7] [8] [9] Examples include beta-emitting 90 Sr sources for intravascular brachytherapy (IVBT), 131 Cs for interstitial permanent implants, miniaturized x-ray emitting electronic sources, and neutron emitting sources for temporary brachytherapy. Also, many innovative brachytherapy applicators have been introduced such as intracavitary balloons for the breast and brain, slotted and notched eye plaques, and applicators with high-Z shielding to considerably alter dose distributions.
In the U.S., manufacturers need to obtain approval from the FDA to introduce new products into the marketplace. In Europe, a similar approval is performed using the CE (Conformité Européenne) Marking to indicate compliance with European regulations. CE Marking has been a legally binding statement by the manufacturer since 1998. The goal usually is to demonstrate equivalence of innovative products to existing medical devices in promotion of patient safety. The AAPM and GEC-ESTRO present guidelines in the current report that address the critical regulatory and dosimetry issues that must be considered by the medical physicist when innovative brachytherapy devices or applications are introduced. In this report, devices are defined to include brachytherapy sources; associated devices like seed spacers, needles, and catheters; and brachytherapy applicators.
Although it is always risky to predict the special challenges and opportunities that are going to be presented by any innovative medical device in the future, one can learn some general principles from past experiences with similar systems. This report presents a history of the development of several brachytherapy devices, which can be used as an educational resource by the investigators. From this prior experience with brachytherapy devices, it is apparent that there is a strong need for developing robust calibration procedures and maintaining a chain of dosimetric consistency across institutions whenever new sources are introduced. However, these requirements should be treated as a starting point for the evaluation of patient safety and efficacy for innovative devices in the brachytherapy community. The original intent was to develop consensus guidelines; however, it became clear that development of specific guidelines was not possible. Therefore, based on the focused review of the issues that have arisen in the past during the introduction of innovative brachytherapy devices or applications, guidelines are made in a generalized fashion.
New devices and applications are considered in the following context: These guidelines reflect clinical practice suggestions of the AAPM and GEC-ESTRO for its members. Beyond this target audience, the vendors, regulatory agencies, and other professional societies should also consider these guidelines to develop good practices for brachytherapy. As these guidelines are made jointly by the AAPM and GEC-ESTRO (as approved by the Advisory Committee on Radiation Oncology Practice), some of the specifically mentioned U.S. agencies, organizations, and standards laboratories should be interpreted in the context of similar arrangements in other countries where applicable. Since it is not practical to list all laboratories and the calibrations they provide, the reader is referred to the Calibration and Measurement Capabilities report of national metrology institutes (NMIs) as maintained by the Bureau International des Poids et Mesures (BIPM, Sèvres, France) as a starting point. 11 Also, specific companies and devices are identified in this work in order to specify adequately the guidelines, but identification of these companies and devices does not imply endorsement by either the AAPM or GEC-ESTRO.
BACKGROUND
Medical use of radiation sources and their marketing are regulated by the FDA in the U.S. as described in Appendix A. Similarly, the Health Products and Food Branch of Health Canada reviews manufacturer applications and issues medical device licenses for brachytherapy sources and related devices that are marketed in Canada. European legislation states that only medical devices that have been certified with a CE Marking according to the Council Directive 93/42/EEC may be sold or exported as commercial products on/to the European market. 12 As examples, an afterloading machine and each individual applicator, transfer tube, connector, and all other devices must be CE certified.
2.A. U.S. FDA regulations
In the U.S., the FDA approval for medical devices started on May 28, 1976 . Therefore, any device that was designed and fabricated prior to this date has been grandfathered FDA approval for its intended use at that time. Generally, if a medical device is being introduced, it can be categorized as being similar or not to an existing medical device. It is the experience of the writing team that the requirements for receiving FDA clearance have been variable across manufacturers and over time.
For the first class, if the new device is substantially equivalent (SE) to a legally marketed device, the regulatory route is a premarket notification, more commonly called a 510(k), as this is the section of the Federal Food, Drug, and Cosmetic Act (FFDCA) that deals with this class of device. SE does not mean identical, rather the indication for use is the same as the predicate device, the material and technology are the same as the predicate, or if they are different there are sufficient data in the submission to show that there are no new safety or effectiveness issues. Usually only technical information is needed to make the evaluation, but in some cases animal or clinical data are required. Typical examples of this class are new 125 I or 103 Pd interstitial brachytherapy seeds, where the new sources differ from existing ones in minor ways such as changes in source configuration or encapsulation. If one wants to use these sources in a clinical trial or investigational study, the sponsor simply needs to obtain approval from the local institutional review board (IRB).
The second class is the one found to be not substantially equivalent (NSE) to a predicate device or a predicate device does not exist. In this case, the regulatory route to market is the premarket approval (PMA) application. This type of application requires both clinical and nonclinical data. Clinical trials must first be approved by an IRB. If the IRB determines that the medical device as it is to be used in the clinical trial is of not significant risk (NSR) to the patient, the trial can begin upon receiving IRB approval. While uncommon, the FDA may disagree with the IRB's NSR designation and require an FDA-approved investigational device exemption (IDE) before the trial begins. An IDE allows an unapproved device to be used in a clinical trial under the set of very specific conditions identified in the trial protocol. As a specific example, the initial use of IVBT sources to treat in-stent restenosis was deemed to be NSR by an IRB. However, the FDA determined that this was a new indicated use of radiation (treating nonmalignant disease in the vascular system), that these devices involved new safety and effectiveness issues, and that these devices presented a significant risk (SR). Thus, clinical trials involving these devices needed an FDA-approved IDE as well as institutionspecific IRB approval.
2.B. Source calibrations
A key component for the accurate delivery of dose by brachytherapy sources is the ability to determine the absolute radiation output from the source at a reference point. For photon sources, this is usually performed by correlating the radiation output to air-kerma strength S K in the U.S. and to reference air-kerma rate in Europe. Since primary measurements of brachytherapy source strength are beyond the capabilities and resources of most clinics, a system of traceability to a primary standards dosimetry laboratory (PSDL) has been established using secondary standards dosimetry laboratories (SSDLs), i.e., Accredited Dosimetry Calibration Laboratories (ADCLs) in the U.S., for most of the sources discussed in this report. In the U.S., the National Institute of Standards and Technology (NIST) is the PSDL that establishes a national primary calibration standard for S K . The national standard is then transferred to the ADCLs. The clinical physicist thus receives a traceable calibrated instrument through the ADCLs. Some SSDLs and ADCLs develop interim standards for source calibrations that are not yet available at PSDLs. Like NIST, the same role is performed by other PSDLs such as the National Physical Laboratory (NPL) in the U.K., the Laboratoire National Henri Becquerel (LNHB) in France, and the PhysikalischTechnische Bundesanstalt (PTB) in Germany. Equivalence of measurements is demonstrated through the International Committee on Weights and Measures Mutual Recognition Arrangement among the countries of these labs as monitored by the BIPM.
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According to the AAPM, brachytherapy source manufacturers are required to annually compare their in-house standard to the NIST standard for low-energy sources, 14 and every two years to a PSDL-traceable standard for high-energy sources, 15 where an energy cutoff of 50 keV is used to separate low-and high-energy sources. It is expected that the transfer standard will be used to characterize the manufacturing source calibration system and that there is a routine quality control program in place to ensure that the manufacturer's source calibration system is operating within statistically expected limits. This chain of traceability to a PSDL is essential to the efficacious and consistent application of brachytherapy sources in widespread use at clinics having varying degrees of expertise for the measurement of source strength. In addition, when errors are discovered or improvements in measurement technology occur and the standard is revised, the chain of traceability allows physicians to revise their prescriptions in a careful and consistent manner. 16 To our knowledge there are no FDA requirements for calibrations, but of course there are NRC regulations for users in the U.S. requiring them to have HDR 192 Ir source calibrations be performed with traceability to the ADCLs.
To illustrate issues that may arise when dosimetry calibration standards are revised or new sources are introduced, consider the brief history of the calibration of 125 I and 103 Pd sources. A primary calibration standard for low-energy, lowdose-rate (LDR) 125 I brachytherapy sources was developed at the National Bureau of Standards (the former name for NIST) in 1984 by Loftus using the Ritz free air ionization chamber. 17 Because of its low sensitivity, four to six sources were mounted in an array to produce an adequate measurement signal. The source calibration was then transferred to the ADCLs. From 1985 through 1988, measurements and Monte Carlo (MC) simulations identified the contribution of titanium x-rays at 4.5 keV, which added 10% to the source output in air with no influence on tissue dose at clinically relevant depths. 18, 19 In 1993, Loevinger revised the calibration standard by introducing the design of the NIST Wide-Angle Free-Air Chamber (WAFAC) for the measurement of these sources. It included an aluminum filter to remove the titanium x-rays, radiation that contributed to measurements by Loftus. 20 The NIST WAFAC allowed measurement of a single source at 30 cm because of its higher sensitivity. The measured airkerma rate at 30 cm distance, corrected for air attenuation between the NIST WAFAC and the source, was presented at 1 m using the inverse square law, yielding S K . During this time, 103 Pd sources were introduced by manufacturers without traceability to a primary calibration standard. Testing and establishment of the NIST WAFAC standard continued through 1998 and a plan for the implementation of the new standard was established to begin on January 1, 1999. A provisional standard was transferred to the ADCLs in 1998. Late in 1999, it was discovered that the NIST WAFAC was producing a systematic error in measurement throughout 1999. The 1999 value for a given 125 I source disagreed with the 1998 standard by 3%. All source models were measured again in 2000, finding that in 1999 there were discrepancies of 2%-7%.
2.C. Brachytherapy dose calculations
For all radiotherapy modalities (including brachytherapy), the accuracy of dose delivery can greatly influence both the benefits and risks to the patient. The radiation treatment has to be delivered within a therapeutic window around the prescription dose as too low a dose could compromise tumor control and too high a dose may cause unnecessary normal tissue toxicity. Although the therapeutic window may be generally considered as narrow in some clinical situations and as wide in other situations, quantitative patient-specific information on the therapeutic window is generally not well known. Thus, the accuracy of dose delivery to the correct target is considered to be a critical factor by the radiation oncology team for all radiotherapy modalities, including brachytherapy. According to Williamson and Rivard, while no major breakthroughs have occurred in the last decade, the uncertainty of brachytherapy dose estimation using MC methods and thermoluminescent dosimeters (TLD) had become better established: 3%-5% (k = 1) for MC and 7%-10% (k = 1) for TLD, 21 where k indicates the coverage factor on the expected distribution. Confidence increased in these quantitative dosimetry techniques after they were applied to more source models. As a result, broader intercomparisons of theoretical and measured dose distributions became possible. In 2005, Williamson and Rivard anticipated the following for the next decade: (a) Improved dose measurement techniques with k = 1 uncertainties near 4%; and (b) development of more accurate dose-calculation engines based upon MC simulation and other transport equation methods for patient-specific treatment planning for brachytherapy. 21 Williamson and Rivard published revised uncertainty budgets for determination of the dose-rate constant Λ, indicating that lower k = 1 uncertainties (1.5%-2% for MC and 6%-7% for TLD) are feasible. 22 The 2011 TG-138 report has confirmed this general trend of improvement in the field of brachytherapy dosimetry. 23 The 2014 report by GEC-ESTRO and AAPM on clinical brachytherapy identified much larger uncertainties when considering the clinical treatment procedure. 24 In 2003, an intersociety group consisting of the American Brachytherapy Society (ABS), the American College of Medical Physics (ACMP), and the American College of Radiation Oncology (ACRO) recommended standards for brachytherapy performance and identified three types of accuracy requirements. 25 These were numerical accuracy, physical dose delivery accuracy, and clinical dose delivery accuracy. Numerical accuracy of a computer-assisted dose calculation should be assessed by comparing its output to independent dose calculations based upon the same algorithm and the same input data. A tolerance of 2% was recommended for numerical accuracy checks, compared to a value of 3% as recommended by TG-40. 26 The intersociety group defined physical dose delivery accuracy as the agreement between calculated dose and dose actually delivered under idealized conditions. This intersociety group recommended that physical dose delivery accuracy have a tolerance of 6%, essentially specifying the accuracy of single-source dose distributions in homogeneous water. However, physical dose delivery accuracy is influenced by source calibration accuracy, the accuracy of the dose calculation algorithm, and the appropriateness of any userselected dosimetric parameters. Furthermore, the intersociety group defined clinical dose delivery accuracy as the agreement between calculated dose and dose actually administered to anatomically defined reference points or surfaces. They recommended that, if assessment of applicator placement shows that the prescribed dose cannot be delivered to the target volume with less than 20% deviation from the prescribed dose, then a reassessment of the procedure is required and the following options should be considered prior to initiating therapy: (i) repositioning the applicator or sources to fulfill the written directive requirements, (ii) adjusting the written directive, or (iii) aborting the procedure.
GUIDELINES
It is difficult to predict future products, their potential new applications, and new problems that may arise. Therefore, the services of a medical physicist are even more critical in the clinical implementation and evaluation of innovative brachytherapy devices and applications. It is suggested that a thorough review of any innovative brachytherapy device or application should be performed by a qualified medical physicist before clinical research or approval for routine clinical use. The medical physicist must play an active role in the evaluation of risks and benefits of new products or new applications, 27 evaluation of preparedness (resource assessment), and evaluation of the regulatory consequences of clinical implementation when the delivered dose substantially differs from the prescription. For the safe implementation of new technologies, the medical physicist should include the suggestions of this report in his/her department policy manual. Further, it is especially important that adopters of new technology diagram their workflow and perform a failure modes and effects analysis to streamline future clinical use.
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3.A. Regulatory requirements
If a new medical device (i.e., research device) fabricated by an individual is to be used on human subjects at the individual's institution, the institution is obligated to document a safety and efficacy analysis. If the device is a new brachytherapy source, ideally it should be listed on the National Sealed Source and Device Registry (NSSDR) of the Nuclear Regulatory Commission (NRC). However, for sources not listed on the NSSDR, the Radiation Safety Committee (RSC) at the individual's institution is obligated to perform a safety analysis similar to that done by an NSSDR reviewer. The RSC at the individual's institution is also obligated to perform a safety analysis if the radiation source is not a radionuclide, i.e., electronic brachytherapy. Similar procedures are to be followed in European countries. This report is silent on necessary approvals for licensing radioactive materials as the topic is outside the approved charge and due to the broad diversity on specific regulatory requirements.
For compliance with Standard 2919 of the International Organization for Standardization (ISO, Geneva, Switzerland) radiation protection requirements for sealed radioactive sources, 33 special form certification by the U.S. Department of Transportation may be necessary for some brachytherapy sources. This is to demonstrate the structural integrity of the sealed source under unusual conditions that could occur during transportation to the individual's institution. Effects of temperature, capsule composition, and capsule dimensions may need to be examined. 34 If the source is a radionuclide, a broadscope licensee in the U.S. has authority to use any of the listed radionuclides allowed by its license. For research purposes, this must be performed under a clinical trial that is approved by the IRB overseeing the individual's institution, regardless of the FDAapproval status of the research device. A suitably trained medical physicist or physician may serve as the principal investigator of the trial.
If an FDA-approved device is to be used for an unapproved clinical indication (i.e., off-label use as described in detail in Appendix A 2) outside of human-use research, 27 The medical physicist should become familiar with the above items if participation is required in a clinical trial using a brachytherapy source or application for research purposes.
The following items are examples of additional brachytherapy-specific information that should be evaluated for all types of usage:
• source decay scheme (plus any daughter or granddaughter products), • source integrity to prevent radioactivity leakage, • procedures for receiving, handling, transporting, and disposing of sources, • confirmation of source sterility when appropriate,
• biocompatibility of the source or device should be ensured, and • any specific source usage issues for clinical use (e.g., source pullback and source delivery), any unusual precautions for shielding staff, or any issues from prescription dose to nearby organs in the patient. The use of robotics in brachytherapy for source delivery is covered in detail within the TG-192 report. 36 Individuals with expertise and background in the appropriate discipline should be consulted. Another issue of concern for brachytherapy sources containing new radionuclides is radionuclide purity. Long half-life radio-impurities may prohibit cremation of the patient after death. In brachytherapy, the desired radionuclide is created from nuclear activation of an enriched or natural target. A nuclear reactor or an accelerator is used with the energy fluence and irradiation time chosen to maximize the isotopic yield of the desired radionuclide. Radiochemical separation is then employed to remove unwanted elements from the irradiated target. Further target refinement is made by waiting for shortlived isotopes to decay to increase the proportion of the desired radionuclide. Unlike for nuclear medicine, to our knowledge there are no radionuclide purity standards for brachytherapy sources. As detailed standards would need to account for photon and beta emissions as a function of radionuclide, it is not possible to set a simple percentage limit in terms of activity, i.e., Bq. However, radionuclide impurities should be limited by manufacturers such that their total dosimetric contributions would be less than 5% of the dosimetric contributions of the primary radionuclide. This value is based on observations of 103 Pd sources 37 and the experience of the writing team for other brachytherapy radionuclides. This suggested limit would be constrained to clinically relevant distances in the vicinity of the implant, and would be subject to the useful source life. If upon decay the radionuclide impurities result in total dose contributions greater than 5% of that due to the primary radionuclide, the medical physicist should account for this change or else remove the source from the clinical inventory. This issue may be assessed by the medical physicist by requesting documentation of the radionuclide purity from the manufacturer and subsequently evaluating the dosimetric influence of any contaminating radionuclides based on their halflives and emission energies. The approach taken by Nuttens and Lucas for brachytherapy sources purposefully containing two different radionuclides may be helpful for performing this assessment. 38, 39 
3.B. Calibration requirements
Suitable instrumentation should exist to determine the source strength of the device. ESTRO Booklet 8 has an extensive description on required features for such instruments. 4 It is suggested that a measure of the source strength (independent from the manufacturer-provided value) be performed by the medical physicist preceding clinical use of the device. This measurement should be traceable to a PSDL, and for photon sources typically will be in units of S K or reference air kerma rate (RAKR) for a sealed source as measured in a re-entrant well-type air ionization chamber having an insert specific to the source design. 6, 14 In the U.S., this calibration will require NIST-traceability with transfer to the ADCLs for availability to U.S. medical physicists. In Europe, the medical physicist should send their instrumentation to an NMI for calibration.
The AAPM and GEC-ESTRO suggest that primary calibration standards be developed for all clinical brachytherapy sources that have received FDA clearance in the U.S. or the CE Mark in Europe. Also, the AAPM and GEC-ESTRO should maintain a formal mechanism for encouraging and supporting the SSDLs to develop interim calibration standards when a primary calibration standard is not available for sources having FDA approval or CE Marking. Because the development of a primary calibration standard is a timeconsuming and expensive process, an interim solution for the safe and efficacious introduction of new brachytherapy sources in the market place is needed. Such situations are likely to be more frequent in the future as several new national and international clinical trials using innovative brachytherapy sources and devices are anticipated.
If NIST or another PSDL has not developed a primary calibration standard for a new source, the SSDLs may establish an interim calibration standard. This interim standard needs to be based upon good metrological procedures by being traceable in some manner to another PSDL calibration standard. Generally, this also involves a publication in a peer reviewed journal. Comparison with a PSDL primary calibration standard when available should be done to determine if there is any discrepancy between the interim standard and the new primary standard. In this case, the focus is to provide a means where all clinics will be delivering a consistent prescription dose whose absolute value may need to be adjusted once a primary calibration standard for that source is developed.
If a research device is at an early stage such that there are no suitable PSDL-traceable calibrations available, the medical physicist should contact a PSDL or SSDL for guidance in developing an in-house calibration standard at the physicist's institution. Development of a rigorous primary or secondary calibration standard (especially for beta-emitters and low-energy photon-emitting sources) can be a major undertaking beyond the capabilities of most academic centers or commercial source developers.
The AAPM is the only organization in the U.S. that has the expertise and committee infrastructure, without a conflict of interest, to maintain close supervision over an interim brachytherapy standard as established at an ADCL. As the PSDL in the U.S., NIST also has close supervision over the ADCLs such as through proficiency tests. These brachytherapy standards are transferred to the clinic via ADCL calibrations. The Sistema Interamericano de Metrologia is a regional metrology organization that includes the NMIs of the 34-member nations of the Organization of American States. In Europe, the European Association of National Metrology Institutes (EURAMET) is the regional metrology organization of Europe. It coordinates the cooperation of European NMIs in fields like research in metrology, national measurement standards, and the calibration and measurement capabilities of its members. ESTRO, as the international professional organization for radiation oncology in Europe, has the infrastructure to interact with EURAMET on the needs and requirements for the field of radiation oncology.
3.C. Dosimetric requirements
It is of course possible for brachytherapy sources to have all regulatory approvals in place and a robust calibration infrastructure available, yet the source would still be deemed deficient by the AAPM and GEC-ESTRO from a dosimetric perspective. 40 The source dose distribution should be well characterized and be evaluated thoroughly before its use. This is often performed by dosimetry investigators using MC methods for radiation transport simulations and/or experimental measurements. The AAPM has issued methodological recommendations to dosimetry investigators for obtaining reference dosimetry parameters for low-and high-energy photon emitters. 2, 15 These dosimetry parameters or some other quantitative characterization of the dose distribution (such as an along/away dose rate table) should be available.
It is suggested that medical physicists utilize societal-issued consensus data on brachytherapy dosimetry parameters when available. In the U.S., these consensus data are posted on the Brachytherapy Source Registry. 10 Using different evaluation criteria, data are also posted on the ESTRO website. 41 If such consensus data are not available, the medical physicist should review the literature and evaluate candidate datasets in the manner described in the 2004 AAPM TG-43U1 report to obtain interim dosimetry parameters. 2 If none exist, the medical physicist should serve as the dosimetry investigator and perform the necessary studies using MC methods and radiation dose measurements for use in clinical brachytherapy treatment planning.
With a well-characterized source dose distribution, the medical physicist should then carefully consider the broad goal of determining the dose to target volumes and critical tissues in the study subjects. This involves the following tasks, which are similarly concerned for when commissioning a new brachytherapy modality:
Basic procedure flow: protocol for source placement and treatment planning.
• Example: preplanning/volume study; image-guided insertion; image-based dose evaluation,
Inputs
• images: patient anatomy and target volume, guidance during applicator insertion, source and applicator localization, and postimplant/intraoperative dose evaluation, all of which may not be applicable to intraoperative radiotherapy (IORT) procedures, • availability of software for brachytherapy treatment planning that is compatible with dose calculation for the source, • source strength and other brachytherapy dosimetry parameters,
• verification and validation of brachytherapy treatment planning system (TPS) for the new device, 3 • planning constraints and goals,
Dose calculations
• single-source dose kernels,
• applicator dose modulation function,
Outputs
• isodose curves, line profiles, and dose-volume histograms (DVHs), • dose specification quantities and criteria, and • maps of dose differences and dose ratios.
3.D. Radiobiological requirements
There are several biological and clinical issues that are primarily evaluated by a radiation oncologist. These issues include consideration of any new long-term effects of radiation linear energy transfer (LET) and relative biological effectiveness (RBE) of source radiation if there is reason to believe that these effects may be substantial or different from those of conventional sources. Equivalent doses for treating specific diseases should be evaluated by a radiation oncologist with the assistance of a medical physicist if there is a reason to believe that the LET or dose rate or other radiobiological factors may alter the effectiveness of radiation. Although the primary responsibility for these biological and clinical issues lies with the radiation oncologist, a medical physicist should assist in this process. Additional information is given in Appendix B.
3.E. Team organization and training
Another important component of introducing newly approved brachytherapy devices or applications is the organization and training of the clinical team. This can be challenging for small clinics where the staffing and resources are minimal. 29 The physicist should evaluate whether or not his/her clinic is ready to introduce new brachytherapy modalities. Each of the members of the clinical team should have to present their qualifications in their given field. Once the team is created, vendor-specific training should follow. Here the details of the treatment device should be explained and the team taught how to safely administer the treatment. Offsite training is most likely used in the early stages, but institutionspecific training should be requested to fit the local team. The onsite training will help illuminate potential problem areas that are unique to the local team configuration and practices. During this training period the local team should minimize distractions in order to acceptably benefit from the training.
Training requirements supplied by the manufacturer are set as part of obtaining approval by the FDA or other regulatory body. Manufacturers of new brachytherapy medical devices may require a certain number of proctored cases. For example, both of the current brachytherapy microsphere vendors (see Sec. 4.G) require three proctored cases to be completed before a site has completed their training. These proctored cases cover all aspects of the case, including ordering the microspheres, determining if the patient meets the treatment indications, performing eligibility exams, assisting with radioactive materials licensing, delivering the patient's treatment and continued patient follow-up.
After the team is created, trained, and has performed solo patient cases at the training center, the team should develop pathways for continuing education and local QA standards. One approach to meet this need is through the RSC. These standards can be placed into the radioactive material license application for both documentation and enforcement. Periodic meetings with disciplines outside the reach of the radioactive materials license, such as medical oncology, are beneficial to the team as methods evolve and indications change. The overall goal for any multidisciplinary treatment modality should be clear communications.
Liver microsphere brachytherapy provides an example of a multidisciplinary team in which a medical physicist must participate. The required specialties in liver microsphere brachytherapy include: individuals to provide the overall management of the cancer patient, serve as the authorized user (radiation oncologist or nuclear medicine physician), perform the vascular catheterization, order and interpret the correct radiology exams, take responsibility for handling the radioactive materials, perform dosimetric calculations, and oversee the radiation safety aspects of the procedure. From one institution to another, the division of these responsibilities will be different as the availability of disciplines varies. In the broadest case, personnel from interventional radiology, radiation oncology, nuclear medicine, medical physics, medical oncology, and radiation safety could all participate in liver microsphere brachytherapy.
BRACHYTHERAPY INNOVATIONS
In order to illustrate the application of the guidelines stated in Sec. 3 to current uses of brachytherapy, this section presents several case studies. These descriptions are organized based on regulatory issues, source calibrations, dose calculation methods, and radiobiological concerns. Highlighted are historical scenarios that caused problems upon clinical implementation, strategies that are now addressed by TG-167 report guidelines, and issues currently unresolved where additional development and guidelines are required. Additional aspects are given in Table I .
4.A. High-dose-rate (HDR) 192 Ir sources and afterloaders
HDR
192 Ir sources have presented several challenges in the U.S. for primary calibration standards. The need for an interim standard was so evident that a calibration standard was developed by the University of Wisconsin in 1993. 43 103 Pd source was calibrated by NIST in 2014 and then transferred to the ADCLs. d There was a primary calibration standard in the U.S. during the period in which treatment was most prevalent. However, NIST no longer performs measurements on intravascular brachytherapy sources, and clinical users in the U.S. may obtain calibrations from the ADCLs. e The ability to calculate dose equivalent, including RBE, is limited. f The TheraSphere manufacturer participates in the NIST Radioactivity Measurement Assurance Program. Dial settings have been determined by NIST for the measurement of TheraSphere in commercially available dose calibrators. However, it is not a primary national standard that has been transferred to ADCLs. g It is possible to generate 3D dose distributions for shielded skin applicators and single-axis treatments using the AccuBoost® system. However, it is not yet possible to generate 3D dose distributions for multi-axis AccuBoost treatments due to the need to model tissue deformation for performing dose summation.
of each other in terms of source strength calibrations. 44, 45 Another HDR remote afterloader is the MultiSource® HDR (Eckert and Ziegler BEBIG GmbH, Berlin, Germany), which delivers brachytherapy with either 192 Ir or 60 Co sources. There currently is no ADCL-approved calibration standard for any of the Eckert and Ziegler HDR sources.
The ADCL ionization chamber calibration technique for 192 Ir source is to average air-kerma calibration factors, interpolating between primary K air standards for 137 Cs gamma rays and medium-filtered M250 kVp x rays. This way, the detector sensitivity to 192 Ir photons may be approximated. The paper by Rasmussen et al. 45 has shown that the various ways of obtaining a calibration coefficient for an ionization chamber for HDR 192 Ir sources also yield the same result as does the methodology mentioned above. After the calibration coefficient for the ionization chamber is obtained, a measurement is taken at seven distances. 43, 46 In this manner, the HDR
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Ir source can be calibrated and that calibration can be transferred to a re-entrant well-type air ionization chamber with subsequent transfer to the end-user's clinic well chamber. These well chambers should then be used to calibrate clinical HDR 192 Ir sources since the seven-distance technique is too cumbersome for proper use in a typical clinical setting and should be performed at PSDLs or SSDLs. However, those clinics without access to calibration of their well chamber by PSDLs or SSDLs will follow the methods described in the ESTRO-issued Booklet 8. 4 With the increased accessibility to PSDLs and SSDLs, this practice is diminishing. Calibration standards for HDR 192 Ir using similar techniques have been developed at a number of European PSDLs such as LNHB, NPL, and PTB, and at the National Research Council of Canada, 47 but not yet at NIST in the U.S. Intercomparisons of these standards have shown good agreement. [48] [49] [50] [51] [52] The preferred method for traceability in clinical source calibrations is to have the well-type chamber calibrated against the traceable standard (e.g., at an ADCL). This calibration should be carried out for each source, including the appropriate source holder made by the well chamber or source manufacturer for that source. Calibration of well ionization chambers is performed using the appropriate source holder, which is a critical part of the calibration system. 45 The dose calculation methods for HDR 192 Ir brachytherapy are well established, and the joint TG-229 report by AAPM and GEC-ESTRO provides detailed information on current HDR 192 Ir source models and their dosimetry parameters. 15 HDR 192 Ir source calibrations are available with PSDL traceability in Europe and with ADCL traceability in the U.S. This case study shows that development of a robust calibration infrastructure can greatly reduce the variability in clinical source calibrations, in this case from over 11% based on userdeveloped standards lacking PSDL or ADCL traceability to less than 2%. 
4.B. HDR 60 Co sources
While the short halflife of 192 Ir (74 days) is beneficial for production of high-specific activity sources with small geometrical dimensions that may be used both for interstitial and intracavitary implants, 192 Ir sources require replacement about every two to four months. In developed countries like the U.S. and most of Europe, this source exchange frequency is not a serious concern as the entire process of source exchange and commissioning can be accomplished within a few days. However, for many developing countries, HDR 192 Ir sources are not easily accessible and occasionally, by the time the customs paperwork and source shipment clearance are completed, a large proportion of useful activity can decay away. 53 Therefore, HDR 60 Co brachytherapy sources (5.27 yr halflife) have been introduced to overcome some of these difficulties.
While HDR 60 Co remote afterloaders were first used in the 1960s, 54 presently four HDR 60 Co remote afterloading systems are commercially available outside the U.S. These are the Ralston remote afterloader (Shimadzu Corporation, Japan), the MultiSource® remote afterloader by Eckert and Ziegler BEBIG GmbH (Berlin, Germany), the Flexisource® 60 Co source as used in the Flexitron remote afterloader (Elekta Brachytherapy, Veenendaal, The Netherlands), and the model GZP6 60 Co source by the Nuclear Power Institute of China (Chengdu, People's Republic of China). While HDR 60 Co sources have CE Marking, the FDA has not reviewed HDR 60 Co sources or remote afterloaders at this time and users in the U.S. cannot yet purchase such equipment.
The PSDL in Germany (i.e., PTB) provides source strength calibrations for HDR 60 Co sources, but there are currently no U.S. PSDLs or ADCLs that offer calibrations. The current U.S. HDR 192 Ir interim calibration standard could be modified to develop a secondary standard for HDR 60 Co brachytherapy sources with direct traceability to the NIST 60 Co teletherapy standard if these brachytherapy sources are ever reviewed by the FDA. Dosimetric characteristics of Ralston HDR 60 Co sources have been determined using MC-based dosimetry. 55 Dosimetric characteristics of MultiSource® HDR 60 Co sources have been evaluated by Ballester et al., Granero et al., and Richter et al. [56] [57] [58] The joint TG-229 report by AAPM and GEC-ESTRO included consensus datasets for these sources. 15 HDR 60 Co remote afterloaders have been used in clinical trials outside the U.S. where regulatory approvals were in place, 59, 60 and there are no substantial radiobiological differences with HDR 192 Ir sources due to both being temporary implants of high-energy photon-emitting sources.
This case study presents the need to go through the regulatory channels for a new source. Following commercial availability, clinical users in the U.S. may consider utilizing the source under IRB approval if FDA approval and calibrations through the ADCLs are unavailable. While there are European-based PSDL-traceable calibration standards for source strength, clinical users in the U.S. require a NISTtraceable calibration standard for general clinical use outside of an IRB-approved protocol. This could be established through creation of an in-house calibration technique.
4.C. LDR 125 I and 103 Pd sources
Because of the growing popularity of prostate implants in the mid-1990s, a variety of new designs of 125 I and 103 Pd sources were developed. Since FDA clearance for these medical devices is predicated on the original interstitial brachytherapy sources and grandfathered for approval, the regulatory approval process for new 125 Pd source models were considered SE to legally marketed sources already in clinical use by the FDA and qualified for premarket notification 510(k). 125 I sources were the first to receive a standard for source strength. 17 103 Pd sources became available in 1988 and were later included in the 1995 TG-43 report. 1 However, a 103 Pd primary calibration standard was not available until NIST developed the WAFAC in 1999. This lack of a primary calibration standard and a PSDL-traceable calibration resulted in a complex history of changes in prescription doses and, consequently, delivered dose. This history is well described by Williamson et al. and is briefly summarized here. 61 Calibrations preceding those made with the NIST WAFAC involved a 109 Cd NIST Standard Reference Material activity standard comparison by the manufacturer, which resulted in −1.7% to +8.7% variations of prescribed dose to delivered dose from 1988 to 1999. After moving away from the 109 Cd activity standard and implementing the NIST WAFAC calibration standard, the prescribed dose still differed from the delivered dose by −4.3% until the WAFAC calibration standard was established via a number of measurements and a Λ value was established in the AAPM 2004 TG-43U1 report. 2 Although the outside dimensions of these 103 Pd sources were nearly identical, their internal geometric structure, such as the shape and materials of the x-ray marker, thickness and materials of the end caps, and radionuclide distribution varied amongst source models. Other sources were designed to improve ultrasound appearance, radiographic visualization, minimize imaging artifacts from computerized tomography (CT), or reduce seed migration. Although the design changes for new 125 I and 103 Pd sources are likely to be minor, these changes can substantially alter the dosimetric characteristics due to the steep dependence of low-energy photon interactions as a function of energy and atomic number. This was demonstrated by variations in Λ of up to 10% for the same radionuclide in different configurations. 62 To a lesser extent, the radial dose functions were also different for different designs of the same radionuclide sources. The 2D anisotropy functions that represent the angular dose dependence around the source can be profoundly different for different source models containing the same radionuclide. Differences in source geometry can also have other dosimetric consequences. For example, Afsharpour et al. demonstrated that variations in seed designs lead to up to 4% variations in interseed attenuation (not taken into account by the AAPM TG-43 protocol), which leads to measurable differences in treatment planning parameters such as prostate D 90 . 63, 64 Consequently, it is imperative that calibration methods and brachytherapy dosimetry parameters be specified for individual source models of 125 I and 103 Pd. Further, the practice of experimental dosimetry for these brachytherapy sources containing lowenergy photon-emitting radionuclides is highly sensitive to the phantom composition. 65, 66 This history of 103 Pd source calibrations presented in this case study underscores the concern for introducing a source into clinical practice with an unstable vendor-maintained relative calibration standard and not having a suitable primary calibration standard. In the absence of regulatory bodies failing to require dosimetric criteria in their approval process, professional societies and voluntary standards can be developed and promulgated to fill the void. The AAPM, U.S. PSDL (i.e., NIST), and SSDLs (i.e., ADCLs) developed the necessary calibration infrastructure needed by clinical users at the time when new 125 I and 103 Pd source models were considered innovative.
14 Without a suitable primary calibration standard, early adopters of new sources should take responsibility for developing an in-house calibration standard with PSDL traceability as appropriate for that source. 131 Cs sources have an average photon energy of approximately 30 keV, which is slightly higher than 125 I and 103 Pd. The model CS-1 Rev2 source was introduced by IsoRay Medical, Inc. (Richland, WA), considered as SE by the FDA, and qualified for premarket notification 510(k) by the FDA for the treatment of cancer. This source model also has CE Marking.
4.D. LDR 131 Cs sources
Before first clinical use, NIST and the ADCLs developed a calibration standard for 131 Cs, having learned from the experience when 103 Pd sources were introduced as described in Sec. 4.C. Soon after clinical use, the initial reported Λ value 67 was determined to be 13% lower than currently accepted values, [68] [69] [70] [71] as demonstrated in several publications by dosimetry investigators soon after this source was made generally available. Subsequently, the brachytherapy dosimetry parameters have been evaluated using several experimental and computational tools and an AAPM consensus dataset has been prepared. The key radiobiological issue presented by this source is that it has a radionuclide having a shorter halflife than any other LDR brachytherapy seed. Because of this shorter halflife, the initial dose rate in permanent 131 Cs seed implants is higher than that for 103 Pd and 125 I permanent implants in order to deliver the same biological effect. Consequently, the prescription for a permanent implant with 131 Cs will differ from 125 I or 103 Pd, and it was necessary to determine the prescribed dose for 131 Cs that would result in the same biological effect as produced by 125 I or 103 Pd implants. For prostate monotherapy, prescription doses of 110 Gy for 131 Cs, 125 Gy for 103 Pd, and 145 Gy for 125 I are common. Before utilizing 131 Cs to treat new disease sites, a careful calculation should be performed using radiobiological models (e.g., linear quadratic model) to deliver similar biologically equivalent dose to predicate sources if available.
As similar to the development of 125 I and 103 Pd sources, this case study highlights the need for established brachytherapy dosimetry parameters preceding general clinical implementation and a careful radiobiological evaluation before widespread clinical use.
4.E. Elongated sources
Elongated brachytherapy sources with active lengths L ≥ 1 cm are readily visualized radiographically and do not migrate as much as single sources. With such sources, it is theoretically possible to obtain better implant quality, with a more homogeneous dose in the proximal tissue region, than using conventional brachytherapy seeds. Encapsulated LDR 192 Ir wires were used primarily in Europe for interstitial brachytherapy since the 1960s and were cut to the desired lengths in clinical practice, but since 2014 are no longer available. Since the wires were designed and first fabricated prior to 1976, these sources were grandfathered approval by the FDA. Due to their longer active lengths than conventional brachytherapy sources, direct calibration of elongated brachytherapy sources is not straightforward. Calibrations of LDR 192 Ir wires were performed in a re-entrant well-type air ionization chamber with either a short sample (<1 cm) snipped from the inventory using the assumption of uniform source strength over the inventory length 73 or with collimated chamber insert to measure sections of an uncut wire. 74 Due to their lowenergy photon emissions, primary calibrations of 103 Pd wires and 103 Pd strings with L ≤ 1 cm have been performed with the NIST WAFAC air-kerma strength standard. Longer sources cannot be calibrated with the NIST WAFAC due to its primary collimator aperture. Consequently, the NIST WAFAC calibration standard is transferred to the ADCLs with 1 cm length sources in a re-entrant well-type air ionization chamber having a length such that the chamber response is uniform over the elongated source length. 42, 75, 76 If a chamber is used without an appropriately long collecting volume, the measurement of source strength can be substantially underestimated. 42, 75 Calculation of dose distributions in the vicinity of elongated brachytherapy sources can be challenging, especially in the close vicinity of a sharp curve. For wire-type sources, there is a general assumption of constant radiation emissions throughout the source length. This assumption should be validated, especially for low-energy photon-emitting sources where its influence would be more pronounced. The pointsource approximation (i.e., 1D source dosimetry formalism) is currently the most commonly used dosimetry methodology for interstitial brachytherapy. Some TPSs accept the 2D source dosimetry formalism, but CT-based imaging may not be able to always identify the source orientation, and no TPS can account for source flexibility. Dose calculations may be accurately performed using conventional treatment planning systems by dividing an elongated source into discrete segments. [77] [78] [79] However, the accuracy of dose calculation methods in the vicinity of elongated brachytherapy sources is sensitive to the spatial resolution of the brachytherapy dosimetry parameters, interpolation and extrapolation techniques, and the dose calculation coordinate system (polar or cylindrical). 80 There are no substantial radiobiological issues between elongated brachytherapy sources and their conventional source counterparts containing the same radionuclide and similar overall source strength.
This case study highlights that implementation of a PSDLtraceable calibration method for elongated brachytherapy sources requires calibration transference to an instrument capable of uniformly measuring the elongated sources. Clinical users should commission a system for assuring linear density constancy, especially for newer low-energy sources. Another issue for elongated brachytherapy sources is identifying a method for dose calculations. Clinical users should commission a method that can accommodate the curvatures intrinsic to the elongated brachytherapy sources being considered, yet produce accurate dose distributions throughout the volume of interest. [82] [83] [84] They had shown that the energies of these sources are high enough to provide adequate penetration depth for intracavitary brachytherapy, yet are low enough to allow customized shielding within the patient with light-weight, high-Z shields. This can be especially useful in treating recurrent gynecological cancers. 85, 86 Using similar arguments, Loft et al. identified the potential for 169 Yb (93 keV mean gamma emission) as a brachytherapy radionuclide. 87 169 Yb is promising because the photon energies are high enough to minimize the photoelectric interactions in soft tissue, yet are low enough to require less radiation shielding than needed for 192 Ir. 88 Other radionuclides such as 170 Tm (129 day halflife), 153 Gd (240 day halflife), and 57 Co (272 day halflife), all with mean photon energy of about 0.1 MeV, have also been considered as new HDR sources. [89] [90] [91] [92] None of these sources are currently available.
4.F. Intermediate energy photon emitters
The FDA has ruled that several applications for HDR 169 
4.G. Electronic brachytherapy sources
As defined by AAPM Task Group 152, Electronic Brachytherapy is "a method of radiation therapy using electrically generated x-rays to deliver a radiation dose at a distance of up to a few centimeters by intracavitary, intraluminal, or interstitial application, or by applications with the source in contact with the body surface or very close to the body surface." 95 In most of the 20th century, brachytherapy treatments were almost exclusively based on radionuclides. However, in the past two decades, two different types of electronic brachytherapy (eBT) sources have been utilized for brachytherapy as alternatives to radioactive sources. These sources, INTRABEAM® (Carl Zeiss Surgical GmbH, Oberkochen, Germany) and Axxent® (Xoft, Inc., a subsidiary of iCAD, Inc., San Jose, CA), offer the possibility for highdose-rate treatments in a wider variety of treatment settings than HDR
192
Ir such as operating rooms and examination rooms with minimal (if any) additional shielding other than a portable shield.
eBT sources present unique electrical and thermal safety issues because high voltage may be present inside the body and the x-ray device may generate a considerable amount of heat. All electrical equipment should follow medical electrical equipment standards such as International Electrotechnical Commission (IEC) 60601 and collateral standards. 96, 97 Most of these recommendations are applicable and offer useful design guidance.
Unlike radionuclide disintegration, the output of the eBT sources does not decay with time and is monitored electronically. Therefore, control of eBT source output is paramount for safe delivery and an accurate understanding of the delivered radiation dose. Another feature unique to eBT sources is that for the same design, the output from the x-ray tube can vary from one tube to another because of possible variations in the fabricated product. Thus, the source strength is measured prior to each fraction with treatment times adjusted proportionately. The INTRABEAM source is calibrated in air using an ionization chamber. This chamber reading is, in turn, related to the dose rate in water at 1 cm from the source on the transverse plane. The INTRABEAM calibration protocol uses a parallel plate chamber and filtered superficial x-ray sources, and is traceable to a kVp x-ray beam standard at a PSDL. Calibration of the Axxent source in terms of air kerma at 50 cm has been established by NIST using the Lamperti free air chamber and transferred to the ADCLs. 98 Thus, the ADCLs can calibrate a well chamber for this measure of source strength.
Treatment planning for the INTRABEAM system is performed using manufacturer-provided parameters. 99 While these are based on published studies, 100-102 the source is not characterized using either the AAPM TG-43 or AAPM TG-61 protocols. TG-43 brachytherapy dosimetry parameters have been determined for the model S700 Axxent source. 103 Due to their low energy photons from a broad continuous energy spectrum and a more distant prescription point than for LDR low-energy sources, eBT dose calculations using the AAPM TG-43 formalism were in error by >20% for most organs examined due to differing radiological properties between tissue and water. 104 For prostate and breast tissues, this was also demonstrated by Landry et al. 105 Thus, TPS-depicted dose for both eBT sources may substantially differ from administered dose due to tissue composition heterogeneities. If the reference data are based on dose to water, the proposed disease site should have a mass density ∼1 and Z eff ∼ 7.4. Alternatively, the reference data can be determined for an alternate medium like muscle or other soft tissue. In this case, the physicist would identify the material associated with the reference data and determine suitable disease site(s) where the treatment planning system would accurately depict absorbed dose to the patient. Admittedly this is not general practice, and the prescription doses for low-energy photon-emitting sources are generally based upon the erroneous dose to water and not tissue. These issues should be carefully evaluated by the medical physicist before clinical implementation. The TG-186 report identifies methods to evaluate these effects. 106 While both eBT sources are used only for temporary HDR implants, dose delivery over a large radial range may cause variations in the biological effectiveness of the absorbed dose as a function of distance from the source. 107 This case study highlights the potential safety problems of eBT sources through their electrical means of generating radiation and heat. There should be compliance with current IEC electrical standards, not commonly concerned for with brachytherapy sources. Medical physicists should strive to provide PSDL-traceable source calibrations, and work with manufacturers to achieve this for their applicable PSDL. NIST and the ADCLs responded to provide an air-kerma standard for one source type with subsequent traceable calibrations to clinical well chambers made available through the ADCLs. Also, the method for calculating clinical dose distributions should be validated by the physicist following commissioning of the eBT system. 105, 106 The physicist should validate that the disease site to be treated is radiologically well-represented by the reference data in the dose calculation formalism. Treatments over large radial ranges may warrant analysis of varying biological effectiveness (see Appendix B).
4.H. Intravascular brachytherapy sources
At the start of the new millennium, IVBT held the spotlight in brachytherapy as a high visibility procedure with few similarities to other brachytherapy procedures. IVBT was the first medical modality in a clinical trial to show substantial reduction of in-stent restenosis following balloon angioplasty. 108 Its use was championed by interventional cardiologists, and the field of radiation oncology leapt at the opportunity to participate in this multidisciplinary procedure to broaden radiotherapy beyond cancer. Most of the devices were beta-emitters, which were not addressed by existent societal guidance documents that focused on photon emitting sources.
Compared to brachytherapy for cancer treatments, a different regulatory paradigm was used when evaluating brachytherapy sources for the treatment of nonmalignant disease in the vascular system. The FDA first determined that the use of radiation to treat disease in the vascular system was a new intended use of radiation. Second, the FDA determined that the use of radiation to treat disease in the vascular system was SR, i.e., a FDA-approved IDE was needed to gather clinical data. Thus for IVBT sources, a PMA application was needed before the product was legally marketed. To date, the only brachytherapy sources requiring a PMA application rather than the more common premarket notification application are IVBT sources and radiolabeled microspheres. The FDA approved the following devices for in-stent restenosis: the 192 109 Currently only the Novoste Beta-Cath system (sold by Best Medical International, Inc.,) is commercially available.
NIST developed a primary calibration standard for these sources before the IDE clinical trials began. This included both photon-emitting and beta-emitting brachytherapy sources. These sources were directly calibrated at NIST for contained activity and/or absorbed dose rate to water at the prescription depth. Also, NIST directly calibrated either a reference or transfer instrument with a radiation source of the same manufacturer and model, which was used as an in-house standard. NIST transferred these calibrations to the ADCLs, which offer calibration services for these sources. If there had not been a PSDL-traceable calibration standard, the clinical user would have needed to establish an interim calibration standard (e.g., extrapolation chamber), which would be more challenging for beta-emitting sources than photon-emitting sources.
The dose rate was calculated using TG-43 (Ref. 1) or TG-60 (Ref. 110) formalisms. Consensus data for the TG-43 brachytherapy dosimetry parameters for the three aforementioned systems were given in TG-149. 81 That report extended the TG-43 formalism in polar coordinates to cylindrical coordinates, which was more appropriate for handling elongated sources. The key IVBT dosimetry problem was that the prescription distance was much smaller than the source length compared to conventional brachytherapy. The AAPM has issued recommendations on dose calculation methods for consistent derivation of absorbed dose. 81, 110 GEC-ESTRO has issued recommendations on standardized terminology, dose prescription, recording and reporting criteria, quality assurance practices, and radiation safety aspects. 111 This case study highlights the need for a clear understanding of the regulatory approval process as rapid acceptance and general clinical utilization of IVBT stressed the brachytherapy community through widespread off-label use with medical physics and radiation oncologist practitioners generally lacking the necessary expertise to evaluate the regulatory implications of the medical decisions. For example, prescription deviations from the simple activity-based approach outlined in the package inserts are considered off-label uses. The source calibration infrastructure rapidly responded to users' needs to provide the necessary facilities for medical physicists. Also, dosimetry investigators had to quickly establish the TG-43 brachytherapy dosimetry parameters necessary for clinical dose calculations.
4.I. Neutron emitting 252 Cf sources
In 1965, Schlea and Stoddard first introduced the concept of using 252 Cf, a neutron emitting radionuclide (halflife 2.65 yr), for intracavitary and interstitial brachytherapy. 112 Neutronemitting 252 Cf sources are unique in brachytherapy as these sources emit radiation with high-LET. 113 Since 1976, several clinical trials have been conducted by Maruyama et al. to test the feasibility and potential of 252 Cf sources and to develop methods for using the neutron-emitting radionuclide in the treatment of cancer. [114] [115] [116] [117] [118] The trials initially treated advanced (Stages III and IV) cervical cancer patients using different doses and schedules; they were extended to include unfavorable presentations of stages I and II because of favorable results in the initial trials where different schedules and sequencing of neutrons and photons greatly altered outcome. Cf mass, or in terms of dose equivalent rate.
121 While the latter measurement may be corrected to obtain air-kerma strength in terms of Gy h −1 m 2 , it is not identical to S K as measured by the NIST WAFAC for photon-emitting brachytherapy sources. The ADCLs do not offer 252 Cf source calibration services, and medical physicists had derived source strength as decayed from the calibration certificate provided by ORNL. 252 Cf sources present challenging problems to radiation dose measurements and calculations because of the emission of both neutrons and high-energy gamma rays. Accurate dosimetry in mixed neutron-gamma fields remains a challenging area of research, and there are no clinical TPSs with FDA approval or CE Marking that can accommodate mixed-field dose. Since their introduction in 1969, dosimetric characteristics of 252 Cf sources have been the subject of clinical and dosimetric research activities. [122] [123] [124] [125] [126] [127] [128] The neutrons deposit energy in tissue by generating secondary charged particles (protons and other heavy charged particles) which have the higher LET. The high-LET radiation confers unique radiobiological advantages because it overwhelms the oxygen effect that renders the hypoxic cells present in most solid tumors resistant to radiation damage. [129] [130] [131] [132] However, high-LET radiation minimizes the influence of sublethal damage that is advantageous for dose fractionation with low-LET radiation. A radiobiological model for the biological effectiveness of HDR 252 Cf brachytherapy has also been developed. 133 This case study indicates that the regulatory status for 252 Cf sources depends on the source model, be it LDR or HDR style, just like for non-neutron-emitting sources. Clinical users in the U.S. should consider using the source under IRB approval before FDA approval and calibrations by the ADCLs are made available. Dose distributions for source models other than the LDR sources lack TG-43 dosimetry parameters, and it is a great challenge to measure these independently due to the mixed-field dose environment. Clinical application of 252 Cf is based upon radiobiology, where a firm understanding of the radiation dosimetry is first required.
4.J. 90 Y microspheres
Microspheres labeled with radioactivity have been used for treatment of cancer in the liver since 1947 (see the review by Kennedy et al.) . 134 Microspheres are injected intra-arterially into the hepatic artery and flow with the blood until they lodge in capillaries. This therapy selectively delivers dose to the tumors because they receive almost all of their blood supply from the hepatic artery, while the liver properly receives 80% of its blood supply from the portal vein. 135, 136 Microspheres require a higher level of concern for radioactivity contamination than conventional brachytherapy sources, and nuclear medicine staff generally assist with the procedure.
Currently there are two manufacturers of radioactive microspheres with FDA approval for human use in the U.S. One of the manufacturers, BTG International, Ltd. (London, UK) markets glass microspheres called TheraSphere®. TheraSpheres were approved with HDE H980006 on 10 December 1999. 137 The instructions for use (IFU) states "TheraSphere is indicated for radiation treatment or as a neoadjuvant to surgery or transplantation in patients with unresectable hepatocelluar carcinoma who can have placement of appropriately positioned hepatic arterial catheters." While microspheres are radioactive solutions, they are not radiopharmaceuticals and were classified by the NRC as manual brachytherapy sources used for permanent implantation therapy. 139 In addition to the information in the manufacturer's packaging and the FDA website, the NRC has provided a radioactive material licensing guidance document on microsphere brachytherapy sources and devices.
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The current prescription paradigm is based on delivery of radioactivity (i.e., Bq) rather than absorbed dose. Activity verification for TheraSphere (NIST-traceable) can be performed with a dose calibrator, such as by Capintec (Ramsey, NJ), having the appropriate setting while SIR-Spheres do not have a NIST-traceable activity calibration (an interim calibration process is available). In general, it is more difficult to establish interim calibration standards and dosimetric parameters for beta-emitting brachytherapy sources than for photon-emitting sources.
For all liver microsphere brachytherapy, a pretreatment liver angiogram study determines the blood supply to the liver. [141] [142] [143] The liver vasculature is meticulously mapped with contrast injection into the hepatic arteries by an interventional radiologist. Special attention is paid to any vessels that could carry microspheres away from the liver and into the stomach, duodenum, or gall bladder. Once the liver blood flow has been mapped, a 99m Tc-labeled macroaggregated albumin procedure is carried out to predict the 90 Y-microspheres distribution within the liver and to calculate the quantity of microspheres required to alter the pulmonary ventilation/perfusion ratio.
While standardized anatomical or biokinetic models have been historically used, this is not adequate and patient-specific approaches should be used. [144] [145] [146] The average dose to an organ does not characterize the dose variability within the organ. Dose information should be represented using 3D dose distributions and DVHs. Imaging of patients using CT or magnetic resonance imaging has typical voxel resolutions on the order of 1 mm. Single photon emission computerized tomography (SPECT) and positron emission tomography (PET) imaging systems can provide 3D patient activity voxels with resolutions of around 3-7 mm. Utilization of PET/CT or SPECT/CT imaging systems permits concurrent imaging of patient anatomy and activity distribution without having to move the patient. New to the field are 3D dose calculations, which may be performed with MC-calculated dose kernels 146 or other deterministic dose calculation methods, 147 and quantitative evaluation of radioactivity spatial distributions from PET and SPECT data with activity quantification uncertainty from SPECT/CT and PET/CT. This case study highlights the need for an understanding of the regulatory approval process, such as use of an IRB when performing off-label use. The calibration infrastructure is not fully in place to provide medical physicists the ability to perform independent, PSDL-traceable activity calibrations for all microsphere types. Furthermore, conventional methods for brachytherapy dose calculation, such as the TG-43 formalism, are not applicable. Sophisticated image-based approaches for dose calculation are under development. Guidance for these issues is included in the AAPM TG-144 report. 
4.K. Collimated applicators and sources
There are two types of collimated applicators that apply brachytherapy with the source positioned more than a centimeter from the patient surface in a noninvasive manner in contrast to most other brachytherapy applications. These include applicators used to treat superficial disease, such as the skin or for IORT, [148] [149] [150] [151] [152] and applicators used to treat at depths exceeding several centimeters, such as for noninvasive imageguided breast brachytherapy (NIBB). 153, 154 The rationale for using shielded applicators for treating the skin or for IORT is to provide collimation of the radiation, yet not to penetrate beyond the target. The applicator face is usually flat, and this helps to provide a uniform dose distribution for elastic anatomy. Both HDR 192 Ir and eBT sources have been used over a variety of treatment sites, and prescription depths generally do not exceed 1 cm. These applicators are manufactured by Varian Medical Systems, Inc. (Palo Alta, CA), Elekta Brachytherapy (Veenendaal, The Netherlands), and Xoft, Inc. Currently there is one manufacturer of NIBB applicators, referred to as AccuBoost by Advanced Radiation Therapy, LLC (Tyngsboro, MA). The rationale for NIBB is to immobilize the breast and standardize the geometry compared to en face irradiation with electrons, to direct the radiation away from the chestwall, and use mammographic image-guidance to guide irradiation of the target. 155, 156 Both applicator types are approved by the FDA and have CE Marking for their respective disease sites. Another type of applicator used in brachytherapy is the shielded applicator as used for treating the vagina or rectum. 157, 158 This shielding may be brought even closer to the source and incorporated into its design. 159, 160 Unshielded source strengths for the HDR 192 Ir or HDR eBT sources used with these applicators are evaluated through conventional means, using a re-entrant well-type air ionization chamber with PSDL-traceable calibration and a parallel-plate air ionization chamber. However, use of the AAPM TG-61 protocol for the Axxent source or a modified external calibration technique has been proposed to calibrate these applicators. 149, 150 For both applicator types, dose is calculated using lookup tables based on MC simulations. This approach may be confirmed using the TG-43 dose calculation formalism where reasonable results may be expected in the region not shielded by the applicator. A dose calculation approach using the TG-43 hybrid method has been developed where the collimated dose distribution is used to derive dosimetry parameters for a virtual source. 154, 161 However, inability to sum dose from orthogonal NIBB brachytherapy beams is a current limitation for understanding the cumulative dose from this treatment modality.
Given the high-dose-rate treatment delivery, there are no substantial radiobiological issues for either type of applicator.
This case study identifies the need to establish dose calculation methods such as by Fulkerson et al. 149, 150 for innovative brachytherapy applicator designs that do not have established TG-43 dosimetry parameters.
4.L. Intracavitary breast balloon brachytherapy
For early stage cancers such as ductal carcinoma in situ, an alternative to whole-breast external-beam radiotherapy (WB-XRT) is partial breast irradiation. By applying the radiation over 4-5 days instead of over 5-6 weeks as is commonly done for EBRT, this procedure is referred to as accelerated partial breast irradiation (APBI). Clinical studies were conducted in the early 1990s using LDR 192 Ir APBI to treat women with interstitial brachytherapy, effectively covering the area around the surgical cavity and only treating women who had a true lumpectomy. 162, 163 In conjunction with HDR 192 Ir sources, the MammoSite® balloon (Hologic, Corp., Bedford, MA) was first used in 2001 as an out-patient alternative to LDR 192 Ir brachytherapy, which required hospitalization for 4-5 days. The dose distributions of the balloon-based technique were compared to the interstitial method, 164 and revealed better coverage of the planning target volume.
Due to the success of the MammoSite applicator, the Axxent balloon applicator was introduced in 2007 by Xoft, Inc. Following this, other multicatheter balloon-type applicators were introduced. These included the MammoSite Multi-Lumen® by Hologic, Corp. (Bedford, MA), Contura® by C. R. Bard, Inc. (Murray, NJ), and SAVI® by CIANNA Medical, Inc. (Aliso Viejo, CA) to provide the radiation oncology community more tools and options to tailor the dose distribution. All three devices use multiple catheters, multiple dwell positions, and variable dwell times. When compared to the original single-channel single-dwell position MammoSite and Axxent balloons, these devices provide better dose coverage to the intended target while delivering dose to the organs-at-risk at an acceptable level.
The MammoSite balloon was approved by the FDA for use as a radiation boost. However, clinicians primarily used them for APBI. As a condition for clearance, the FDA required the manufacturer to include a warning in the product labeling stating that the safety and effectiveness of MammoSite as a replacement for WB-XRT to treat breast cancer had not yet been established. In addition, the device was only approved as a boost therapy in conjunction with WB-XRT following lumpectomy. Given widespread off-label use of these breast balloon applicators and the consequent need for each center to pursue clinical use under an IRB approved study, the Radiation Therapy Oncology Group (RTOG) and National Surgical Adjuvant Breast and Bowel Project (NSABP) conducted a phase III clinical trial (RTOG 0413/NASBP B-39) to evaluate APBI as monotherapy for stage I and II breast cancers. This trial is closed to enrollment after enrolling approximately 2050 subjects, patient follow-up is ongoing. A body of clinical data has grown to support use for both the FDA approved indication (boost for WB-XRT) and for the off-label intent (APBI-only monotherapy). [165] [166] [167] [168] [169] [170] [171] [172] There are no brachytherapy source calibration issues with breast balloon applicators as the HDR source is a separate entity.
While calculations of dose distributions in patients implanted with breast balloon applicators is a straightforward clinical task, it has been shown that dose at the air:skin interface is underestimated by up to 20% due to differences in radiation scatter conditions between the implant and the computational TPS environment. 106 Further, the presence of air can also alter the dose distribution in a substantial manner. 173 Though these effects on dose have existed since the use of LDR 192 Ir sources, the TG-186 report makes recommendations on how to utilize TPS that correct for radiation scatter conditions.
There are no radiobiological issues as there are societalrecommended dose fractionation schedules using state-of-theart radiobiological models. 174 This case study highlights the need for a clear understanding of the scope of regulatory approval for a medical device as there was widespread off-label use of APBI-based balloon brachytherapy without having IRB approval. Prospective users should consult their local IRB and review FDA or CE Marking materials in addition to NSSDR literature to prevent any inappropriate off-label use.
4.M. Intracavitary brain balloon brachytherapy
The dosimetric rationale for intracavitary breast balloon brachytherapy may be similarly applied to the brain, where conventional brachytherapy implants using seeds may cause unacceptably nonuniform dose distributions. 175, 176 The GliaSite® applicator is available from IsoRay Medical, Inc. (Richland, WA), for brachytherapy of primary, metastatic, or recurrent brain tumors. The double-walled balloon approved by the FDA (K132996) for these uses is filled with a liquid solution of either 125 I or 131 Cs after surgical placement. The radioactive solution is drained from the balloon following the prescribed treatment time (2-4 days) after delivering the desired dose.
Source strength provided by the manufacturer is based on a NIST-traceable calibration standard that was developed by the manufacturer. Source strength is independently checked by the end-user using a nuclear medicine dose calibrator with a NIST-traceable activity calibration for a specific vial type and for each radionuclide. These dose calibrators differ from the re-entrant well-type air ionization chambers used for assaying source strength for brachytherapy sealed sources. 6, 14 Further, the ADCLs do not offer services for transferring calibration standards to clinical users for liquid sources.
The prescribed treatment time is calculated from the inflated balloon diameter, injected solution volume, and desired dose. 177, 178 Treatment planning data for 125 I and 131 Cs are based on tabulated values provided by the manufacturer. These data were obtained using MC simulations by IsoRay Medical, Inc., and an independent dosimetry investigator, with results being in good agreement. For 131 Cs, results were parameterized such that a clinical physicist could calculate the dose parameters for nontabulated volumes, margin depths, and treatment duration. This approach is analogous to entering brachytherapy dosimetry parameters into a TPS for conventional brachytherapy seeds.
There are no substantial radiobiological issues for this type of applicator because of the temporary implant duration, similar dose rates, and similarity in photon energies of 125 I and 131 Cs. This case study highlights the need for including qualified dosimetry investigators and establishing calibration standards as PSDL calibration standards (and ADCL calibration services). Additionally, image-based treatment planning techniques are needed for calculating 3D image-based dose distributions.
4.N. NonCOMS eye plaques
Eye plaques are manually -loaded radionuclide applicator systems. Most of the clinical evidence for eye plaque brachytherapy of uveal melanoma was obtained under the Collaborative Ocular Melanoma Study (COMS). 179, 180 The COMS was formed in 1986 as a multi-institutional cooperative clinical trial group with the goal of conducting a prospective randomized clinical trial to compare enucleation vs radiation therapy for medium sized lesions (apical height of tumor 2.5-10 mm and basal diameter ≤16 mm). While COMS-style plaques initially used only 125 I seeds, 103 Pd and 131 Cs seeds have been employed. Dosimetry for COMS-style plaques is examined in detail within the TG-129 report, 181 while the forthcoming TG-221 report examines nonCOMS style plaques.
In addition to COMS-style plaques, eye plaques using 106 Ru/ 106 Rh have been used with success primarily in Europe, but also for the past 15 years in the U.S. COMS plaques were designed and fabricated prior to 1976, and were grandfathered for FDA IDE approval. Newer plaque designs have been developed with notches or slots. [181] [182] [183] [184] [185] [186] Plaques introduced after 1976 having newer designs that operate using a different fundamental scientific technology; e.g., seed collimation, than a legally marketed device, i.e., COMS plaques, may require manufacturers desiring to market the device to submit for premarket notification and review by the FDA or for CE Marking to determine if they are SE in comparison to existing medical devices.
For plaques using LDR seeds such as 125 I, 103 Pd, or 131 Cs, 187 the source calibration procedure is straightforward, and the seeds are measured preceding plaque assembly. Beta-emitting plaques containing the longer-lived 106 Ru/ 106 Rh radionuclides require the clinical medical physicist to calibrate the plaque in terms of dose preceding clinical use.
COMS included a strict physics protocol to provide consistency of dose delivery, and mandated that all participants use the same point-wise dosimetry parameters in a dose calculation formalism similar to the TG-43 approach. No corrections for silastic or gold plaque were allowed, nor was the line-source formalism used. The calculations did not allow the use of finite, realistic geometry for the patient. Using these assumptions, the dose was calculated and the prescribed dose to the tumor apex for selected patients was 85 Gy. 188 Later, more accurate dose calculation algorithms such as MC simulations indicated that the actual dose delivered in COMS patients was about 76 Gy for 125 I and 67 Gy for 103 Pd. Thus, if a physician wants to reproduce the COMS clinical experience and adopt the more accurate new dosimetry methods (correction for silastic and gold plaque, finite and realistic geometry for the patient), then the prescribed dose should be decreased by about 10% and 20% for 125 I and 103 Pd, respectively. 189 This highlights some of the dosimetric considerations that can arise when an innovative brachytherapy applicator is introduced.
While COMS provided benefit to the brachytherapy community through standardization to compare this modality to enucleation, the brachytherapy community has lost this consistency. Eye plaque brachytherapy is now delivered with innovative plaques and a wide variety of prescription doses, prescription points, and implant durations. 181 For example, changing implant duration for COMS plaques from 7 to 3 days increases the biologically effective dose by 14%. 190 This case study highlights a type of medical device where there are several plaque models in clinical use, but without FDA approval or CE Marking. Institutions using these devices must either obtain IRB approval or request the manufacturer to obtain FDA approval or CE Marking. There are no recommended methods in place for the end-user to perform an independent measurement of the assembled plaque. 191 The dosimetric influence of customized plaques remains to be evaluated and illustrates the need for national guidelines for clinical implementation of new sources and applicators. Simulations using MC methods for radiation transport should be used to quantitatively compare newer plaques to the more established COMS-style plaque for providing similar dose deliveries through prescription scaling. 182, 189 These issues are being examined jointly by the AAPM and GEC-ESTRO under Task Group 221.
SUMMARY
The current report presents methods for evaluating innovative brachytherapy devices and applications for the safe and consistent implementation of this radiotherapy modality. An introduction to the regulatory processes is given, including listing on the U.S. NRC NSSDR, U.S. DOT requirements of sealed sources and devices, the IEC 60601 Medical Electrical Equipment Standard, U.S. FDA approval process for review devices substantially equivalent to legally marketed devices, the CE marking standard, and IRB oversight and institutional requirements for research and clinical use. The current report also issues guidelines for the calibration of brachytherapy sources, ability to obtain 3D dose distributions for clinical implementation, evaluation of radiobiological issues, and commissioning issues such as team formulation. While medical physicists are the target audience for this report, vendors, regulatory agencies, and other professional societies should give consideration to these AAPM and GEC-ESTRO guidelines.
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U.S. Nuclear Regulatory Commission
The NRC is a U.S. government agency that was established by the Energy Reorganization Act in 1974, and began operations on 19 January 1975. The NRC took over the role of oversight of nuclear energy matters and nuclear safety from the Atomic Energy Commission (AEC). Oversight of nuclear weapons, as well as the promotion of nuclear power, was transferred to the Energy Research and Development Administration (ERDA) by the same act, thereby eliminating the AEC. In 1977, ERDA became the U.S. Department of Energy (DOE). Like its AEC predecessor, the NRC oversees reactor safety, reactor licensing and renewal, radioactive material safety and licensing, and waste management (storage and disposal). The NRC's mission is to regulate the U.S. civilian use of byproduct, source, and special nuclear materials to ensure adequate protection of public health and safety, to promote national defense and security, and to protect the environment. This mission was amended in 2005 to include naturally occurring radioactive materials.
Regulatory authority over the medical use of ionizing radiation is shared among several federal, state, and local government agencies. The NRC (or the responsible Agreement State) has regulatory authority over the possession and use of byproduct, source, or special nuclear material in medicine. Byproduct material is used in some calibration sources, radioactive drugs, bone mineral analyzers, portable fluoroscopic imaging devices, brachytherapy sources, gamma stereotactic radiosurgery devices, and teletherapy units used in medicine. A few cardiac pacemakers are still powered by special nuclear material batteries.
With the exception of the use of radioactive drug capsules containing ≤37 kBq (1 µCi) of 14 C urea for in vivo diagnostic use in humans, all internal or external administrations of byproduct material, accelerator-produced radioactive material, or naturally occurring radioactive material to human patients or human research subjects must be performed in accordance with a medical use license or authorization issued pursuant to NRC's regulations in 10 CFR Part 35, "Medical Use." NRC licenses the medical use of byproduct materials in diagnostic devices in the practices of dentistry and podiatry. The medical use of plutonium in nuclear powered pacemakers is licensed pursuant to 10 CFR Part 70.
The NRC oversees medical uses of nuclear material through licensing, inspection, and enforcement programs. The NRC issues medical use licenses to medical facilities and authorized physician users, develops guidance and regulations for use by licensees, and maintains a committee of medical experts to obtain advice about the use of byproduct materials in medicine. The Advisory Committee on the Medical Uses of Isotopes, comprised of medical physicists, physicians, medical scientists, and other healthcare professionals, meets twice a year to be briefed by, and provide advice to, the NRC staff on current initiatives in the medical uses of radioactive materials. The NRC (or the responsible Agreement State) also regulates the manufacture and distribution of these products with information available for the NRC Medical Uses Licensee Toolkit 192 and specific information on medical products.
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In the U.S., the NRC and the Agreement States evaluate the design of sealed sources and devices to safely contain radioactivity under the conditions of their possession and use. These evaluations are summarized in registrations on the NSSDR as maintained by the NRC. These registration certificates contain detailed information on the sources and devices such as how they are permitted to be distributed and possessed (i.e., specific license, general license, or exempt), on their design and function, radiation safety characteristics, and on limitations of their use. Registration is often a first step for new sources or devices. Sources or devices listed on the NSSDR meet a minimum level of design and radiological safety, but this is not an indicator of meeting AAPM or GEC-ESTRO guidelines on source calibrations and dosimetry. For sources not having dedicated regulatory sections, Part 35.1000 allows the NRC to provide regulation through license conditions and posted guidance.
U.S. Food and Drug Administration
The FDA oversees good practices in the manufacturing of radiopharmaceuticals, medical devices, and radiationproducing products (e.g., x-ray machines and accelerators). The states regulate the practices of medicine and pharmacy and administer programs associated with radiation-producing x-ray machines and accelerators.
The FDA is an agency of the United States Department of Health and Human Services and is responsible for assuring the safety of most types of foods, dietary supplements, drugs, vaccines, biological medical products, blood products, medical devices, radiation-emitting products, veterinary products, and cosmetics. The Center for Devices and Radiological Health (CDRH) is the branch of the FDA responsible for the approval of all medical devices before they can be legally marketed in the United States, as well as overseeing the manufacturing, performance, and safety of these devices. The definition of a medical device is given in the FFDCA, and it includes products ranging from a simple toothbrush to complex devices such as implantable brain pacemakers. CDRH also oversees the safety and performance of medical and nonmedical devices which emit certain types of electromagnetic radiation. Examples of CDRH-regulated devices include brachytherapy sources, airport baggage screening equipment, television receivers, microwave ovens, tanning booths, and laser products. CDRH regulatory powers include the authority to require technical reports from the manufacturers or importers of regulated products, to require that radiation-emitting products meet mandatory safety performance standards, to declare regulated products defective, and to order the recall of defective or noncompliant products. The CDRH also conducts limited amounts of direct product testing.
FDA approval for medical devices started in 1976. Therefore, any device that was designed and fabricated prior to 1976 has been grandfathered FDA approval for its use at that time. Further, if a device is made by an investigator for one case with special situations and is not marketed, FDA needs only to be informed but no approval is required.
The FDA's role is to assure the public that medical devices are safe and effective when used as described by the "label," i.e., the label on the product, the package insert, or other documents that accompany the device. The FDA issues approval or clearance for the device when it is determined that the device is safe and effective if used as described in the IFU. The FDA clearance allows the manufacturer to promote and sell the device for the indications described in the labeling. If used as described in the label, payors following the guidelines of the Centers for Medicare and Medicaid Services usually reimburse medical providers for that specific use in patients. However, licensed practitioners of medicine have the right to use approved devices for an individual patient in any way they deem appropriate, either according to the label or "offlabel" unless such use has been deemed SR. Many novel drugs and devices have resulted from creative off-label use by experienced medical practitioners.
Any new device including a new brachytherapy source is generally evaluated for its approval as a medical device by the FDA based on relation to a legally marketed predicate device and includes its risk factor. If a medical device is being introduced, it can be categorized into two groups: (1) similar to an existing device and (2) one for which no comparable device exists. For devices in the first group, the vendor has to provide the FDA enough evaluation data from either the vendor or some independent investigators in order to receive approval and to market the device. Specifically, the vendor has to demonstrate for approval that new material or technology in the device did not raise new safety and/or effectiveness issues. In order for the FDA to determine if the new device may be categorized as an SE device with equivalence to an existing device, the vendor must submit device specifics prior to the approval. If the device does not qualify for SE categorization and therefore falls into the second group, then sufficient information including clinical and nonclinical data must be provided showing that it is safe and effective for its intended use.
An SR device is defined as an investigational device if it is one of the following: (1) intended as an implant and presents a potential for serious risk to the health, safety, or welfare of a subject; (2) purported or represented to be for a use in supporting or sustaining human life and presents a potential for serious risk to the health, safety, or welfare of a subject; (3) for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health and presents a potential for serious risk to the health, safety, or welfare of a subject; or (4) otherwise presents a potential for serious risk to the health, safety, or welfare of a subject. New brachytherapy sources or applicators that are NSE will typically meet one or more of the SR definitions.
The FDA-approved IDE will contain an explicit protocol to be followed during the trial; conditions for use in the protocol are very specific. In general the IDE involving ionizing radiation products will include the following: nonclinical data including animal data, bench testing, dosimetry, specific indication for use, trial protocol, test hypothesis, statistical analysis including sample size needed to test the hypothesis, specific primary safety and effectiveness endpoints for trial, secondary endpoints for trial, patient inclusion criteria, patient exclusion criteria, informed consent form, and case report forms.
Part of the information submitted by the manufacturer for a PMA is intended to provide the FDA with sufficient clinical and nonclinical data to show that the device provides reasonable assurance of safety and effectiveness for its intended use. This information will form the bulk of the material in the device's label. This includes the indicated use of the device, IFU, advertising literature, and oral information from company representatives. The FDA can only evaluate safety and effectiveness of the device for its intended use based on the information submitted in the PMA so this is the only information in the labeling. Hence, if the device is used in a manner not included in the PMA, it is being used off-label. Here off-label refers to any use of the device that is not specified in its approved labeling.
When an approved medical product is used for an unlabeled indication it is considered to be used in an "off-label" manner. This is allowed under the practice of medicine when used by a qualified licensed healing arts practitioner. The FDA Modernization Act of 1997 explicitly includes a section on the practice of medicine which allows the clinician to make a medical decision (practice of medicine) to use a medical device approved for one indication in an off-label manner for another. However, it is then the clinician's (or clinical team's) responsibility to evaluate the safety and effectiveness for this off-label use of the device for the individual patient being treated. If the majority of patients are treated in the same off-label manner with a SR device at an institution, there is a gray area that this should be conducted under a clinical trial. If human use research is being conducted, then prior IRB approval and an FDA-approved IDE are required. If the results of a study involving off-label use are published, it could be interpreted as conducting an unapproved clinical trial involving a SR medical device. Thus the sponsor of the clinical trial using a SR device is the one responsible for obtaining both approval from the IRB and for an FDA-approved IDE. The sponsor can be either the manufacturer of the device or an individual investigator.
Any time an investigator decides to treat a number of patients with a SR device in the same off-label manner, the investigator should realize that a clinical trial is being conducted and as part of the clinical trial the investigator should have obtained approval from the local IRB as well as an FDA-approved IDE.
Health Canada brachytherapy regulations
Health Canada is a department of the Canadian federal government that is responsible for regulations on medical devices. Following the establishment of the Canadian Department of Health in 1919, the Food and Drugs Act was voted upon in 1920 by the Parliament of Canada. Medical devices such as brachytherapy sources and devices are regulated by the Therapeutic Products Directorate, which is within the Health Products and Food Branch of Health Canada. This governmental Branch has many similarities to the U.S. FDA where regulations are primarily designed for premarket licensing and licensing is needed for the selling and marketing of medical devices. It is the manufacturer's responsibility to apply for market authorization, where evidence is demonstrated for the quality, safety, and efficacy of a medical device as required by the Food and Drugs Act and Regulations of Canada. The regulations set by Health Canada have set classification levels for medical devices based on the level of risk to the patient. These classification levels range from 1 to 4, with 4 representing the highest risk. Brachytherapy sources containing radionuclides are class 3. The approval method outlined in Sec. 2.A for investigational devices is similar between Canada and the U.S.
European Union regulatory structure
The CE Marking is an important step before a medical device can be sold in Europe. Since June 1998 the CE Marking is a legally binding statement by the manufacturer. It is not a mark of quality, rather a sign that the product has reached the requirements of special European device directives, Medical Devices Directive (MDD 93/42/EEC), In Vitro Diagnostic Device Directive (IVDD 98/79/EC), or the Active Implantable Medical Device Directive (AIMDD 90/385/EEC). Most medical devices, like brachytherapy devices, are in the scope of the MDD 93/42/EEC. All manufacturers that can demonstrate compliance with the MDD are allowed to apply the CE Marking on their products. A requirement for this is to have a full quality management system according to ISO 13485 for products up to a risk classification class IIb (see below). The local notified bodies will in such cases check the development documents of the product in the frame of an audit procedure.
At the time of writing, CE Marking is required in 28 countries within the European Union. Additionally, Norway, Iceland, Switzerland, Turkey, and Liechtenstein are signatories of the European Economic Area and require CE Marking. Switzerland has transposed the Medical Devices Directives into their national law, and thus the CE Marking requirements.
European medical devices are classified into different groups: Class I devices are low risk devices. Medium risk devices are subdivided into two groups: Class IIa and Class IIb devices. Class IIa devices are for example diagnostic ultrasound devices or hearing aids. Class IIb devices have a greater risk than Class IIa devices. To this group belong, e.g., surgical lasers, heart defibrillators, and radiation treatment devices (including brachytherapy devices) where product failure can result in serious health risk for the patient or other personnel. The highest risk devices are in Class III. In this category are for instance stents, intracardiac catheters, and breast implants. Classification rules are specified in the Annex IX of the MDD. Furthermore, for devices of Classes I (sterile or measuring devices) II, IIa, IIb, and III, a quality management system must be implemented that complies with Annex II or V of the MDD. Many manufacturers use ISO 13485 to meet those requirements. In this ISO standard a comprehensive management system for medical devices is described. After the quality management system is implemented, a technical file must be prepared for medical devices of all classes. It includes among other components a device description, product specification, technical drawings, performance testing, risk analysis, and a clinical validation. If the company has no place of business in Europe, the appointment of an authorized qualified representative in Europe is necessary. This representative acts as liaison between the company and the competent authorities in Europe. The CE Marking certificate is issued after the successful review of the technical file and the quality management system by a notified body. To maintain the certification, the auditing must be repeated every year. Finally, a declaration of conformity must be prepared. In this short document, the companies state that they are in full compliance with the MDD. Moreover, it is required to translate the relevant documentation such as the information for use and the labeling of the medical device for those European countries where the device will be sold. Even if this point is not addressed in the MDD, it is necessary to be in concordance with national laws.
In summary, it is of course possible for a brachytherapy source or device to have both FDA approval and CE Marking and to also be listed on the NSSDR, yet lack key clinical aspects such as having a PSDL-traceable calibration or satisfying societal dosimetric prerequisites.
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APPENDIX B: RADIOBIOLOGICAL AND CLINICAL CONSIDERATIONS
The effectiveness of brachytherapy implants is influenced by several radiobiological factors. In LDR permanent implant brachytherapy, the tumor cells are subjected to continuous irradiation of low-energy photons with instantaneous dose rate varying in both space and time and in some HDR brachytherapy regimens they are subjected to 1-5 fractions separated by 1-5 days. The prescribed initial dose rates vary from approximately 5 cGy/h to 30 cGy/h for permanent implants using 125 I, 103 Pd, or 131 Cs sources to about 12 cGy/s for HDR 192 Ir temporary brachytherapy. The duration needed to deliver, for example, 80% of the total dose varies from minutes for temporary HDR 192 Ir implants to approximately 22 days for permanent LDR 131 Cs implants or 140 days for 125 I implants. With such diverse spatial and temporal variations, the physical absorbed dose distribution alone becomes insufficient to fully characterize the biological responses of different tumors and normal tissues at risk. Yet accurate representations of delivered physical dose are a necessary first step for introducing any new brachytherapy source. 106 The cell repopulation, cell loss, migration, and sublethal damage repair all compound with each other producing substantial effects on cell killing during the course of dose delivery. In assessing the effectiveness of brachytherapy with an innovative device, there is a need to consider the interplay between the spatial and temporal patterns of dose delivery and the underlying cell kinetics. In addition, with LDR brachytherapy, the dose delivery occurs over many weeks with the "delivery position" varying greatly such as walking, running, and sleeping. With EBRT and HDR, the "delivery position" is, relatively speaking, more consistent. Distance to surrounding critical structures is therefore more variable during the LDR dose delivery, a factor that should be considered when discussing dosimetric uncertainties in different modalities.
Over the last several decades, various models have been developed to characterize the interplay of spatial-temporal patterns of dose delivery with the underlying cell kinetics in brachytherapy and EBRT. For permanent implants, an analytic expression of biologically effective dose has been derived by Dale based on the linear-quadratic (LQ) cell inactivation model. 194 This model has been used by many investigators to examine various issues related to prostate implants. In reviewing clinical trials using innovative brachytherapy devices, one must keep in mind that radiobiological modeling is intrinsically organ specific. For a given organ, factors that are important to the calculation of radiobiological indices include not only the physical dose or dose-rate distribution but also the properties of intrinsic dose response, tissue architecture of the irradiated organs, fractionation factors (e.g., the α/ β ratio in the LQ cell inactivation model), cell repopulation, and sublethal damage repair. The 2006 GEC-ESTRO Guidelines on brachytherapy for cervical cancer and the 2009 AAPM TG-137 report on permanent prostate brachytherapy provide recommendations on radiobiological models and biophysical parameters. 195, 196 The key intent of these reports is to promulgate consistent biological effective dose through prescriptions and protocols having equivalent dose-time fractionation.
In addition, the radiobiological effects for a given dose may be different than those for conventional sources if the energy spectrum of the emitted radiation, the radiation type, or the dose rate is different. If the new brachytherapy source has such unique features, then it may be necessary to conduct radiobiological studies to investigate the microdosimetric aspects of the emitted radiations such as the LET and its influence on the RBE and the oxygen enhancement ratio (OER). In these cases, a clinical trial may be necessary to show that the device is safe and effective for the proposed indication for use.
Before device manufacturers start clinical trials on an innovative brachytherapy device, they should conduct extensive nonclinical studies. Nonclinical studies involve bench studies, in vitro (test tube), and in vivo (animal) experiments using wide-ranging doses of the study device to obtain preliminary efficacy, toxicity, and pharmacokinetic information. Such tests assist manufacturers in deciding whether a drug/device candidate has scientific merit for further development as an investigational new drug (IND) or an IDE.
Typically, clinical trials for new drugs involve four phases. Phase 0 studies are first-in-human trials conducted in accordance with the 2006 FDA Guidance on exploratory investigational new drug/device studies. Phase 0 trials are also known as human microdosing studies. Phase 0 trials include the administration of single subtherapeutic doses of the study drug/device to a small number of subjects (10-15) to gather preliminary data on the agent's pharmacokinetics.
In phase I trials, a small group of patients (20-80) who have end-stage disease and lack other treatment options are selected to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a drug/device. Healthy volunteers may be recruited to gather data on certain aspects of the trial. Phase I trials normally include dose-ranging, also called dose escalation, studies so that the appropriate dose for therapeutic use can be found.
Phase II trials are performed on larger groups (20-300) and are designed to assess how well the drug/device works, as well as to continue phase I safety assessments in a larger group of volunteers and patients. Phase II studies are sometimes divided into phase IIA (designed to assess dosing requirements) and phase IIB (designed to study efficacy).
Phase III trials are randomized controlled multicenter studies on large patient groups (300-3000 or more) and are aimed at being the definitive assessment of how effective the drug/device is, in comparison with the currently accepted standard treatment. Because of their size and comparatively long duration, these are the most expensive, time-consuming, and difficult trials to design and run, especially for chronic diseases like cancer.
Phase IV trials are also known as postmarketing surveillance trials. Phase IV trials involve the safety surveillance (e.g., pharmacovigilance) and ongoing technical support of a drug or device after it receives approval to be sold.
There are three types of clinical trials: (1) those that require only IRB approval and are normally at a single institution for a marketed device, home-made device, or off-label use of an approved device, (2) those that require both IRB approval and an FDA-approved IDE, and are normally multicenter to gather information for marketing a new medical device, and (3) co-operative group trials, which may be sponsored by the National Cancer Institute (NCI) to study various treatment protocols with marketed devices.
If a clinical trial uses a medical device which meets the FDA definition of SR, a FDA-approved IDE must be obtained in addition to IRB approval. This would also apply to drugs used in radiation therapy, such as requiring IRB approval and an FDA-approved IND to utilize an unapproved PET tracer (e.g., [
18 F]-fluoro-3 -deoxy-3 -:-fluorothymidine) to guide radiotherapy dose escalation. Clinical trials for devices typically involve only two phases. The sample size is much smaller than for drug clinical trials as the sample size is determined to be that which will have statistical significance (usually at the 95% confidence level) to support the trial hypothesis. Additionally, the sample size for device clinical trials is just for the participants meeting the inclusion/exclusion criteria and not for a larger population typical of drug clinical trials. Part of the IDE approval process involves the applicant submitting nonclinical data as well as a protocol for conducting a clinical trial, which must be designed to show that the device is safe and effective for the proposed indication for use. However, clinical trials have been used rarely in the introduction of innovative brachytherapy devices because of the difficulties in patient accrual and the need for long-term follow-up in cancer trials. An exception has been in the evaluation of IVBT sources for prevention of restenosis after angioplasty. A number of phase III studies were carried out for IVBT with different devices as thousands of patients were accrued in a few years. Only a well-designed clinical trial can evaluate the clinical efficacy of brachytherapy compared to that for existing therapeutic approaches. This is especially pertinent for treatment of disease other than cancer where the clinical safety and efficacy of radiation are not well established and a new class of human disease is to be treated by a radiation emitting device.
Most cooperative group trials involving brachytherapy have been designed with a goal of achieving a dose delivery accuracy of ±15%. It is commonly accepted that the radiation output of therapeutic devices should be known with accuracy better than a few percent in the entire target volume. Unlike EBRT, brachytherapy presents an even more challenging problem because the dose gradient in the vicinity of the brachytherapy sources is very steep and position and orientation of each source in the patient must also be known to a high precision. In addition, brachytherapy sources need to be calibrated, and therefore a practical mechanism is needed to ensure that source strength provided by the vendor in a package delivered to a clinic has the correct value. All of these factors are essential to accurately determine the dose distributions in individual patients and must be addressed when an innovative brachytherapy device or application is introduced.
